Name of this trial: Artemide Lung-03
What type of cancer is this for? Metastatic Non-Small Cell Lung Cancer (NSCLC)
Who is this trial for? Participants who have not had treatment for their metastatic non-squamous lung cancer. Early-stage treatment in curative setting is permitted.
What biomarkers are involved? PD-L1
What is the National Clinical Trial #? NCT06627647
Brief summary of this trial: Double-blinded trial of Rilvegostomig or Pembrolizumab (Keytruda) in combination with chemotherapy for first line treatment of metastatic non-squamous, non-small cell lung cancer, whose tumor express PD-L1. Both arms of study will receive the same chemotherapy regimen, and the Rilvegostomig/Pembrolizumab will be blinded to site and patient.
Need to know: All participants in this trial will be receiving some form of treatment. There is no placebo. The trial is looking for best possible medication in this sub-disease population of lung cancer. All medications being used are either already approved for this disease type or are approved for similar disease type in either earlier or later stages of the disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Tropion Lung 12
What type of cancer is this for? Stage 1 Non-Small Cell Adenocarcinoma Lung Cancer
Who is this trial for? Patients who are requiring surgical resection for early-stage lung cancer who have high-risk pathological features (visceral pleural invasion, lymphovascular invasion).
What biomarkers are involved? n/a
What is the National Clinical Trial #? NCT06564844
Brief summary of this trial: Randomized trial of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig, Rilvegostomig Monotherapy Versus Standard of Care (observation/chemotherapy), following Complete Tumor Resection
Need to know: Patients will need to consent to trial prior to surgical resection procedure. Patients will be randomized 4-8 weeks after surgery and will know which medications they will receive. Treatment will be over a 12 month period, then follow up is required to review overall and disease free survival.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Artemide Lung 02
What type of cancer is this for? Metastatic Squamous Cell Non-small Cell Lung Cancer
Who is this trial for? Squamous cell non-small cell lung cancer patients who have not received any prior treatment for metastatic disease. You may have received treatment for early-stage lung cancer.
What biomarkers are involved? PD-L1 which will be confirmed by central lab
What is the National Clinical Trial #? NCT06692738
Brief summary of this trial: This is a phase 3, randomized, double-blinded trial of Rilvegostomig or Pembrolizumab in combination with chemotherapy for patients who have not been treated for metastatic disease. All patients will receive chemotherapy and will receive 1 of 2 drugs mentioned above, however because the trial is blinded, no one will know which of the medications you are receiving, other then the sponsor.
Need to know: All participants in this trial will be receiving some form of treatment. There is no placebo. The trial is looking for best possible medication in this sub-disease population of lung cancer. All medications being used are either already approved for this disease type or are approved for similar disease type in either earlier or later stages of the disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Interpath-002
What type of cancer is this for? Resected Stage II, IIIA, IIIB, non-small cell Lung Cancer
Who is this trial for? Patients who have had their lung cancer completed resected, with no evidence of disease and have completed post-surgical chemotherapy.
What biomarkers are involved? none
What is the National Clinical Trial #? NCT06077760
Brief summary of this trial: This is a phase 3, double-blinded, randomized, placebo- and active comparator controlled trial of V940 vaccine or placebo, plus pembrolizumab after non-small lung cancer resection. This is considered adjuvant treatment (treatment given after primary treatment to reduce risk of cancer returning) where all participants will receive pembrolizumab immunotherapy with/without vaccine.
Need to know: Randomization is 1:1 for either vaccine or placebo, no one will know what patient is receiving (double-blinded).Vaccine is tailored to each individual based on their cellular makeup and is given as injection in the muscle every 3 weeks. Pembrolizumab is given IV every 6 weeks.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: KRAScendo
What type of cancer is this for? Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Stage IIIc-Stage IV
Who is this trial for? Patients who have progressed during or following treatment with at least 1 prior line of therapy, but no more than 3 prior lines of therapy in the metastatic setting.
What biomarkers are involved? KRAS G12C
What is the National Clinical Trial #? NCT06497556
Brief summary of this trial: This is a phase 3, randomized trial evaluating safety and efficacy of new oral drug Divarasib. Patient will be randomized to either study drug Divarasib, Sotorasib (standard of care drug), or Adagrasib (standard of care drug). All medications are oral and provided by sponsor or via medication card.
Need to know: Genetic mutations will be confirmed from central lab using previous biopsy tissue. Scans will occur every 6 weeks to confirm treatment efficacy. Each cycle of treatment is 21 days, and the first couple cycles will require more frequent visits and labs to confirm tolerability and safety, further cycle visits will spread out to monthly.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: LIVIGNO-4
What type of cancer is this for? Non-Small Cell Lung Cancer, Non-Squamous Cell Cytology
Who is this trial for? Patients with Lung Cancer that has metastasized to other areas of body who have never received treatment for their disease.
What biomarkers are involved? NO EGFR, or NO ALK mutations allowed.
What is the National Clinical Trial #? NCT06236438
Brief summary of this trial: Randomized study looking at Livmoniplimab plus Budigalimab in combination with standard of care chemotherapy vs. Pembrolizumab plus standard of care chemotherapy.
Need to know: Patients must not have had any treatment for their metastatic lung cancer to be eligible for this trial. Patients may have received treatment for earlier stage of lung cancer as long as it was 6 months or greater from the time of progression of disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial: JUSTAR-001
What type of cancer is this trial for? Limited Stage, Small-cell Lung cancer
Who is this trial for? Patients with limited stage small cell lung cancer who have not progressed after initial chemotherapy/radiation.
What biomarkers are involved? None
National Clinical Trial # NCT06095583
Brief Summary of trial: Study is looking to compare and evaluate efficacy of new drug Tifcemalimab combined with Toripalimab vs. PLACEBO after consolidation chemotherapy for small cell lung cancer. This is a blinded study, so patients will not know whether they are receiving investigational drug or not.
Need to know information: Must not have received prior immunotherapy for small-cell lung cancer, and cannot have extensive stage/metastatic small cell lung cancer.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]
Name of Trial? Sunray-01
What type of Cancer is this for? Non-small cell Lung cancer
What biomarkers are involved? KRAS G12C-mutation, PD-L1 expression
National Clinical Trials # NCT06119581
Brief Summary of trial: Locally advanced, or metastatic non-small cell lung cancer, never treated. This is first line treatment with study drug LY3537982 (pill) or placebo, in combination with immunotherapy and chemotherapy.
Need to know information: No prior treatment for lung cancer. We will do mutation testing to determine eligibility from prior biopsy/blood sample. This is a blinded trial with study drug LY3537982/placebo. All patients will receive the oral drug but the provider nor research team will know whether you are getting drug/placebo.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email [email protected]
Name of this trial: Tropion-Lung 10
What type of cancer is this for? Locally advanced or Metastatic Non-Squamous Non-small cell lung cancer
Who is this trial for? Patients who have lung cancer that is not treatable with curative surgery of chemoradiation. Patients must not have received prior treatment for advanced stage non-small cell lung cancer.
What biomarkers are involved? PD-L1 expression of ≥ 50% which will be determined by central lab.
What is the National Clinical Trial #? NCT06357533
Brief summary of this trial: Phase 3, Randomized, global trial of Datopotamab Deruxtecan in combination with Rilvegostomig, or Rilvegostomig monotherapy, or Pembrolizumab monotherapy. Randomization is a 2:1:2 for the 3 different arms.
Need to know: Must be non-squamous histology. Will require baseline eye exam for all arms of trial. Patients randomized to Datopotamab Deruxtecan will need further eye exams throughout trial.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email [email protected]